Rocket Pharmaceuticals (RCKT) Expected to Release Quarterly Earnings on Thursday

Rocket Pharmaceuticals (NASDAQ:RCKT) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.39) per share and revenue of $0.20 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings data on Monday, August 10th. The biotechnology company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.22. During the same period in the prior year, the firm earned ($0.62) EPS. On average, analysts expect Rocket Pharmaceuticals to post ($1.36) EPS for the current fiscal year and ($1.44) EPS for the next fiscal year.

Rocket Pharmaceuticals Stock Up 1.2%

RCKT opened at $2.47 on Tuesday. The company has a market cap of $271.16 million, a P/E ratio of -14.53 and a beta of 0.50. The business’s 50-day moving average price is $2.94 and its 200-day moving average price is $3.45. The company has a current ratio of 9.24, a quick ratio of 9.24 and a debt-to-equity ratio of 0.05. Rocket Pharmaceuticals has a 12 month low of $2.16 and a 12 month high of $5.45.

Insider Transactions at Rocket Pharmaceuticals

In other news, General Counsel Martin Wilson sold 75,364 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $3.40, for a total transaction of $256,237.60. Following the completion of the transaction, the general counsel directly owned 598,489 shares of the company’s stock, valued at approximately $2,034,862.60. This represents a 11.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Christopher Stevens sold 36,658 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $3.50, for a total transaction of $128,303.00. Following the transaction, the chief operating officer directly owned 505,784 shares of the company’s stock, valued at approximately $1,770,244. This trade represents a 6.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 125,977 shares of company stock worth $432,273 in the last 90 days. Corporate insiders own 21.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on RCKT. Cantor Fitzgerald restated an “overweight” rating on shares of Rocket Pharmaceuticals in a research report on Wednesday, October 7th. Leerink Partners decreased their price target on Rocket Pharmaceuticals from $7.00 to $4.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 7th. Needham & Company LLC upgraded Rocket Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a research report on Wednesday, September 16th. Jefferies Financial Group reissued a “hold” rating and set a $2.95 price objective on shares of Rocket Pharmaceuticals in a research note on Wednesday, October 7th. Finally, Chardan Capital reissued a “buy” rating and set a $11.00 price objective on shares of Rocket Pharmaceuticals in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.77.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare and devastating diseases. The company uses lentiviral and adeno-associated virus (AAV) technologies to address genetic disorders with significant unmet medical needs, including hematologic, metabolic, and cardiovascular conditions.

Rocket’s pipeline has included RP-L102 for Fanconi anemia, a rare inherited bone-marrow-failure disorder; RP-L201 for leukocyte adhesion deficiency-I, an immune disorder; and gene therapy programs targeting Danon disease and arrhythmogenic cardiomyopathy.